ClinicalTrials.gg
RecruitingNCT06246188Updated Nov 20, 2026

RCT to Compare Stress-CMR Using Mobile MRI vs. MRI for Inpatients

An observational study in Coronary Artery Disease, sponsored by German Heart Institute. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by German Heart Institute · Observational

How we know

Updated Nov 20, 2026Now RecruitingSite recruiting status changed+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
250
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 365 studies in Coronary Artery Disease with a site in Germany — 46 open to participants now, 71 under way, 3 of them phase 3. Coronary Artery Disease · Germany.

Planned enrollment
84th of 117
250 · median 550
Started
2026
with 6 others
Observational
117 of 365
22 open now
Primary completion
2027-06
later than 41 of 70 live
Registered
346th of 365
by date

Among the 365 studies in Coronary Artery Disease with a site in Germany, this one is the 84th largest by planned enrollment of the 117 observational ones that give a count, is one of 7 that started in 2026, is one of 117 observational ones, reaches primary completion later than 41 of the 70 other live ones, and was the 346th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

46 of the 365 studies in Coronary Artery Disease with a site in Germany are open now. Recruiting first, the newest first:

40 more — sign in →

All 46 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 365 studies in Coronary Artery Disease with a site in Germany, or all of them as a file.
02

Study summary

Coronary artery disease (CAD) is the clinically relevant manifestation of atherosclerosis affecting the coronary arteries. CAD is associated with an increased risk of morbidity and mortality and typically presents as angina pectoris or dyspnea. Non-invasive imaging techniques are recommended for the diagnosis of CAD. Of particular importance is stress perfusion cardiac magnetic resonance imaging (CMR), which is distinguished from other recommended diagnostic modalities by its high diagnostic accuracy and the absence of exposure of patients and healthcare professionals to ionizing radiation. Consequently, stress perfusion CMR has been assigned a Class I recommendation in international cardiology guidelines.

The aim of this study is to demonstrate the feasibility of transferring the clinical routine workflow for the diagnostic evaluation of patients with suspected coronary artery disease (CAD) from stationary, specialized centers to mobile MRI units.

This will be demonstrated by comparing two groups. In one group, stress CMR examinations will be performed using mobile MRI units, while in the other group, examinations will be conducted in stationary imaging facilities. Participants will be randomly assigned to one of the two groups.

Read the detailed description

The diagnostic examinations conducted as part of this study will be performed using stress perfusion cardiac magnetic resonance imaging (CMR) with the pharmacologically active agent regadenoson and the contrast agent gadobutrol. A total of 250 patients with a clinical suspicion of hemodynamically significant coronary artery disease (CAD) will undergo stress perfusion CMR using the pharmacologically active vasodilator regadenoson and the contrast agent gadobutrol. Examinations will be performed in either mobile or stationary MRI units. By introducing stress CMR as a mobile diagnostic service, state-of-the-art, highly accurate diagnostic imaging can also be made available in rural areas. This will enable timely diagnostic examinations close to patients' homes, both for patients with abnormal findings and suspected coronary artery disease and for further diagnostic evaluation of patients with already established CAD. Mobile stress CMR diagnostics will provide the treating specialist with additional information to support clinical decision-making regarding the timely initiation of targeted treatment in the cardiac catheterization laboratory, potentially having a positive impact on subsequent treatment and prognosis.

The study aims to achieve the following objectives:

To demonstrate the feasibility of easily performing stress perfusion CMR in a mobile setting using a short, patient- and user-friendly MRI protocol that is identical to the protocol established in clinical routine practice and recommended by professional societies.

Our hypothesis is that there are no differences in the performance of stress CMR examinations in a mobile setting compared with a stationary setting. The primary endpoints are the proportion of successfully completed and evaluable stress CMR examinations with at least adequate image quality.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • Cardiac MRI
  • Stress perfusion cardiac MRI
  • Regadenoson
  • Diagnosis
  • Rural Region
  • mycocardial perfusion defect
  • mobile MRI
  • CMR
  • Cardiac Magnetic Resonance
  • Gadobutrol
04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of adults with a clinical indication for invasive cardiac diagnostic evaluation due to suspected or known coronary artery disease (CAD).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adults based one of the following criteria:

  • Male or female subjects aged ≥18 years
  • Clinical indication for invasive cardiac diagnostic evaluation in patients with suspected or known coronary artery disease (CAD)
  • Patient fully responsible and can understand/sign the study from a legal aspect
  • Patients who have provided written to participate in the study and to the processing of their personal data

Exclusion criteria

Exclusion Criteria:

  • Patient refusal to participate
  • Any to perform an Stress-Perfusion MRI exam
  • Contraindication to the cardiac MRI examination (e.g. inability to hold breath; severe claustrophobia, metallic devices such as pace makers)
  • Sensorineural hearing loss and tinnitus
  • Known pregnancy or lactation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
250 participants (estimated)
Patient registry
No

Groups and cohorts

  • Mobile Setting Group

    Adult patients with suspected coronary artery disease will undergo a clinical indicated stress CMR examination in a mobile MRI unit using stress agent Regadenoson and contrast agent gadobutrol. Stress cardiac examination will be performed In accordance with the protocol established in clinical routine practice and consistent with the MRI examinations performed in the stationary setting group.

    Diagnostic Test: Cardiac stress CMR examinations for clinical diagnostic in adult patients with suspected coronary artery disease

  • Stationary Setting Group

    Adult patients with suspected coronary artery disease will undergo a clinical indicated stress CMR examination in a stationary MRI unit using stress agent Regadenoson and contrast agent gadobutrol. Stress cardiac examination will be performed In accordance with the protocol established in clinical routine practice.

    Diagnostic Test: Cardiac stress CMR examinations for clinical diagnostic in adult patients with suspected coronary artery disease

Interventions

  • Diagnostic testCardiac stress CMR examinations for clinical diagnostic in adult patients with suspected coronary artery disease

    Performing stress cardiac MRI in mobile MRI units vs. stationary MRI units for clinical diagnosis in adult patients with suspected coronary artery disease

06

What researchers measure

Primary outcomes

  1. Proportion of unsuccessful or non-evaluable stress CMR examinations

    The primary endpoint is the proportion of unsuccessful or non-evaluable stress CMR examinations (e.g., due to adverse events or insufficient image quality) under an identical examination protocol. In the stationary setting, this proportion is approximately 3%. It is assumed that the proportion will also be 3% in the mobile setting, with mobile stress CMR being considered non-inferior provided that the proportion of unsuccessful or non-evaluable stress CMR examinations does not exceed 10%. Based on these assumptions, a non-inferiority test with a one-sided significance level of 2.5% will have 80% power if 94 patients are enrolled in each study arm.

    Time frame: at baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Nagel E, Klein C, Paetsch I, Hettwer S, Schnackenburg B, Wegscheider K, Fleck E. Magnetic resonance perfusion measurements for the noninvasive detection of coronary artery disease. Circulation. 2003 Jul 29;108(4):432-7. doi: 10.1161/01.CIR.0000080915.35024.A9. Epub 2003 Jul 14. PubMed 12860910 ↗
  • Hundley WG, Hamilton CA, Thomas MS, Herrington DM, Salido TB, Kitzman DW, Little WC, Link KM. Utility of fast cine magnetic resonance imaging and display for the detection of myocardial ischemia in patients not well suited for second harmonic stress echocardiography. Circulation. 1999 Oct 19;100(16):1697-702. doi: 10.1161/01.cir.100.16.1697. PubMed 10525488 ↗
  • Kelle S, Roes SD, Klein C, Kokocinski T, de Roos A, Fleck E, Bax JJ, Nagel E. Prognostic value of myocardial infarct size and contractile reserve using magnetic resonance imaging. J Am Coll Cardiol. 2009 Nov 3;54(19):1770-7. doi: 10.1016/j.jacc.2009.07.027. PubMed 19874990 ↗
  • Tschope C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB, Hare JM, Heidecker B, Heymans S, Hubner N, Kelle S, Klingel K, Maatz H, Parwani AS, Spillmann F, Starling RC, Tsutsui H, Seferovic P, Van Linthout S. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol. 2021 Mar;18(3):169-193. doi: 10.1038/s41569-020-00435-x. Epub 2020 Oct 12. PubMed 33046850 ↗
  • Weiss KJ, Nasser SB, Bigvava T, Doltra A, Schnackenburg B, Berger A, Anker MS, Stehning C, Doeblin P, Abdelmeguid M, Talat M, Gebker R, E-Naggar W, Pieske B, Kelle S. Long-term prognostic value of vasodilator stress cardiac magnetic resonance in patients with atrial fibrillation. ESC Heart Fail. 2022 Feb;9(1):110-121. doi: 10.1002/ehf2.13736. Epub 2021 Dec 6. PubMed 34866358 ↗
  • Sengupta PP, Kramer CM, Narula J, Dilsizian V. The Potential of Clinical Phenotyping of Heart Failure With Imaging Biomarkers for Guiding Therapies: A Focused Update. JACC Cardiovasc Imaging. 2017 Sep;10(9):1056-1071. doi: 10.1016/j.jcmg.2017.07.001. PubMed 28882290 ↗
  • Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, Charron P, Corrado D, Dagres N, de Chillou C, Eckardt L, Friede T, Haugaa KH, Hocini M, Lambiase PD, Marijon E, Merino JL, Peichl P, Priori SG, Reichlin T, Schulz-Menger J, Sticherling C, Tzeis S, Verstrael A, Volterrani M; ESC Scientific Document Group. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022 Oct 21;43(40):3997-4126. doi: 10.1093/eurheartj/ehac262. No abstract available. PubMed 36017572 ↗
  • Kramer CM, Barkhausen J, Bucciarelli-Ducci C, Flamm SD, Kim RJ, Nagel E. Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update. J Cardiovasc Magn Reson. 2020 Feb 24;22(1):17. doi: 10.1186/s12968-020-00607-1. PubMed 32089132 ↗
  • Pavon AG, Porretta AP, Arangalage D, Domenichini G, Rutz T, Hugelshofer S, Pruvot E, Monney P, Pascale P, Schwitter J. Feasibility of adenosine stress cardiovascular magnetic resonance perfusion imaging in patients with MR-conditional transvenous permanent pacemakers and defibrillators. J Cardiovasc Magn Reson. 2022 Jan 13;24(1):9. doi: 10.1186/s12968-021-00842-0. PubMed 35022037 ↗
  • Doltra A, Skorin A, Hamdan A, Schnackenburg B, Gebker R, Klein C, Nagel E, Fleck E, Kelle S. Comparison of acquisition time and dose for late gadolinium enhancement imaging at 3.0 T in patients with chronic myocardial infarction using Gd-BOPTA. Eur Radiol. 2014 Sep;24(9):2192-200. doi: 10.1007/s00330-014-3213-y. Epub 2014 May 15. PubMed 24828537 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Jun 2027, 7 months after the start.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 7 months is below that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Jun 2025 → Nov 2026, primary completion Dec 2025 → Jun 2027 and completion Dec 2025 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2024
First posted
Feb 7, 2024
StartActual
Nov 9, 2026was Jun 2025
Primary completionEst.
Jun 30, 2027was Dec 2025
CompletionEst.
Dec 31, 2028was Dec 2025
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 20, 2026
Sites
Deutsches Herzzentrum der Charité is now Recruiting
Nov 20, 2026
Start date
Jun 1, 2025→Nov 9, 2026
Nov 12, 2026
Primary completion
Dec 31, 2025→Jun 30, 2027
Nov 12, 2026
Study completion
Dec 31, 2025→Dec 31, 2028
Nov 12, 2026
Enrollment
80→250
Nov 12, 2026
Eligibility
1 inclusion criterion edited, 2 added, 6 removed; 1 exclusion criterion edited, 1 added, 7 removed
What changed in the criteria
Inclusion criteria
  • EditedAdults with known or suspected coronary artery disease based one of the following criteria:
  • RemovedAbnormal CMR without stress in a previous CMR measurement (e.g. new onset of wall motion abnormalities or reduced LVEF)
  • RemovedReferral from local cardiologist based on one of the following criteria:
  • RemovedPatients has a diagnosed coronary artery disease based on other methods
  • RemovedPatients has a high-risk profile based on risk stratification using clinical evaluation (ESC-Score > 5%), the assessment of LV function by resting echocardiography, and, in the majority of cases, non-invasive assessment of ischaemia or coronary anatomy.
  • RemovedPatients demonstrate chronic kidney disease (CKD III or higher) and diabetes
  • RemovedPatients demonstrate history of peripheral artery disease (PTA/Stent) or TEA of the carotids or previous operation of atherosclerotic aortic aneurysms
  • AddedClinical indication for invasive cardiac diagnostic evaluation in patients with suspected or known coronary artery disease (CAD)
  • AddedPatients who have provided written informed consent to participate in the study and to the processing of their personal data
Exclusion criteria
  • EditedAny contraindication to perform an Stress-Perfusion MRI exam
  • RemovedKnown Hypersensitivity to the active substance or to any of the excipients in Regadenoson or GE-267
  • RemovedAny contraindication to aminophylline or theophylline: hypotension, unstable cardiac arrhythmias and acute coronary symptoms
  • RemovedUnstable angina that has not been stabilized with medical therapy
  • RemovedSevere hypotension
  • RemovedDecompensated states of heart failure
  • RemovedSevere Arrhythmias
  • RemovedSecond or third degree atrioventricular (AV) block or sinus node dysfunction, unless these patients have a functioning artificial pacemaker
  • AddedSensorineural hearing loss and tinnitus
Nov 12, 2026
Interventions
Added Diagnostic test: Cardiac stress CMR examinations for clinical diagnostic in adult patients with suspected coronary artery disease; removed Diagnostic test: Cardiac MRI using Regadenoson and GE-267
Nov 12, 2026
Primary outcomes
1 added, 2 removed
What changed in the outcomes
  • AddedProportion of unsuccessful or non-evaluable stress CMR examinationsTime frame: at baseline
  • RemovedDetect mycocardial perfusion defectTime frame: at baseline
  • RemovedEvaluate the image quality of GE-267Time frame: at baseline
Nov 12, 2026
Secondary outcomes
4 removed
What changed in the outcomes
  • RemovedRecommendation of the patient to further procedureTime frame: 6-8 months
  • RemovedComparison of stress-cMRI result and result of invasive diagnosticTime frame: 6-8 months
  • RemovedTotal examination timeTime frame: within 2 hours after baseline
  • RemovedAdverse EffectsTime frame: within 2 hours after baseline
Nov 12, 2026
Title
Use of Stress-CMR Using Regadenoson and GE-267 in Adult Patients with Known or Suspected Coronary Artery Disease→RCT to Compare Stress-CMR Using Mobile MRI vs. MRI for Inpatients
across 2 updates, Nov 12, 2026 – Nov 20, 2026
Show all 2 updates
  1. Nov 20, 2026
    Not yet recruiting→Recruiting
    Deutsches Herzzentrum der Charité is now Recruiting
    Title Comparison of the Use of an Outpatient/Mobile MRI Procedure With an Inpatient MRI Procedure in Adult Patients With Known or Suspected Coronary Artery Disease (CAD)→RCT to Compare Stress-CMR Using Mobile MRI vs. MRI for Inpatients
    + 1 other change: date precision
  2. Nov 12, 2026
    Start date Jun 1, 2025→Nov 9, 2026
    Primary completion Dec 31, 2025→Jun 30, 2027
    Study completion Dec 31, 2025→Dec 31, 2028
    Enrollment 80→250
    Eligibility 1 inclusion criterion edited, 2 added, 6 removed; 1 exclusion criterion edited, 1 added, 7 removed
    What changed in the criteria
    Inclusion criteria
    • EditedAdults with known or suspected coronary artery disease based one of the following criteria:
    • RemovedAbnormal CMR without stress in a previous CMR measurement (e.g. new onset of wall motion abnormalities or reduced LVEF)
    • RemovedReferral from local cardiologist based on one of the following criteria:
    • RemovedPatients has a diagnosed coronary artery disease based on other methods
    • RemovedPatients has a high-risk profile based on risk stratification using clinical evaluation (ESC-Score > 5%), the assessment of LV function by resting echocardiography, and, in the majority of cases, non-invasive assessment of ischaemia or coronary anatomy.
    • RemovedPatients demonstrate chronic kidney disease (CKD III or higher) and diabetes
    • RemovedPatients demonstrate history of peripheral artery disease (PTA/Stent) or TEA of the carotids or previous operation of atherosclerotic aortic aneurysms
    • AddedClinical indication for invasive cardiac diagnostic evaluation in patients with suspected or known coronary artery disease (CAD)
    • AddedPatients who have provided written informed consent to participate in the study and to the processing of their personal data
    Exclusion criteria
    • EditedAny contraindication to perform an Stress-Perfusion MRI exam
    • RemovedKnown Hypersensitivity to the active substance or to any of the excipients in Regadenoson or GE-267
    • RemovedAny contraindication to aminophylline or theophylline: hypotension, unstable cardiac arrhythmias and acute coronary symptoms
    • RemovedUnstable angina that has not been stabilized with medical therapy
    • RemovedSevere hypotension
    • RemovedDecompensated states of heart failure
    • RemovedSevere Arrhythmias
    • RemovedSecond or third degree atrioventricular (AV) block or sinus node dysfunction, unless these patients have a functioning artificial pacemaker
    • AddedSensorineural hearing loss and tinnitus
    Primary outcomes 1 added, 2 removed
    What changed in the outcomes
    • AddedProportion of unsuccessful or non-evaluable stress CMR examinationsTime frame: at baseline
    • RemovedDetect mycocardial perfusion defectTime frame: at baseline
    • RemovedEvaluate the image quality of GE-267Time frame: at baseline
    Secondary outcomes 4 removed
    What changed in the outcomes
    • RemovedRecommendation of the patient to further procedureTime frame: 6-8 months
    • RemovedComparison of stress-cMRI result and result of invasive diagnosticTime frame: 6-8 months
    • RemovedTotal examination timeTime frame: within 2 hours after baseline
    • RemovedAdverse EffectsTime frame: within 2 hours after baseline
    Interventions Added Diagnostic test: Cardiac stress CMR examinations for clinical diagnostic in adult patients with suspected coronary artery disease; removed Diagnostic test: Cardiac MRI using Regadenoson and GE-267
    Title Use of Stress-CMR Using Regadenoson and GE-267 in Adult Patients with Known or Suspected Coronary Artery Disease→Comparison of the Use of an Outpatient/Mobile MRI Procedure With an Inpatient MRI Procedure in Adult Patients With Known or Suspected Coronary Artery Disease (CAD)
    + 5 other changes: verification date, responsible party, oversight details, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06246188
Lead sponsor
German Heart Institute
Responsible party
Sebastian Kelle (Univ.-Prof. Dr. med., German Heart Institute) — Principal investigator
First posted
Feb 7, 2024
Start date
Nov 9, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Sebastian Kelle, Prof. Dr.
Contact
sebastian.kelle@dhzc-charite.de
+493045931182
Gisela Thiede, Dr.
Contact
gisela.thiede@dhzc-charite.de
+4915209192843
Sebastian Kelle, Prof. Dr.
principal investigator · Deutsches Herzzentrum der Charité

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion